该药为E-选择素抑制剂,以内皮细胞为靶点,阻断骨髓细胞与白血病髓样细胞的粘附。
在对 388 名复发/难治性急性髓系白血病 (AML) 患者进...查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011861 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 20:35
$Glycomimetics(GLYC)$ 8-K Current report, items 5.03, 5.07, and 9.01 Accession Number: 0001558370-24-006459 Act: 34 Size: 320 KB 网页链接查看全文
Glycomimetics(GLYC)05-07 04:05
$Glycomimetics(GLYC)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001558370-24-006793 Act: 34 Size: 7 MB 网页链接查看全文
Glycomimetics(GLYC)06-04 21:35
$Glycomimetics(GLYC)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001558370-24-008882 Act: 34 Size: 8 MB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011872 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011867 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011862 Size: 5 KB 网页链接查看全文
Glycomimetics(GLYC)05-02 04:35
$Glycomimetics(GLYC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-011869 Size: 5 KB 网页链接查看全文
chuminhua05-07 13:19
3/6,GlycoMimetics $Glycomimetics(GLYC)$ 的在研血癌治疗 Uproleselan (GMI-1271) 的一项关键研究未能达到主要生存终点,导致公司股价周一暴跌 79%。
该药为E-选择素抑制剂,以内皮细胞为靶点,阻断骨髓细胞与白血病髓样细胞的粘附。
在对 388 名复发/难治性急性髓系白血病 (AML) 患者进...查看全文
产业链观察05-06 23:18
#药闻简讯# 2024年5月6日,$Glycomimetics(GLYC)$ 公布Uproleselan治疗复发性/难治性AML的三期临床最新数据,研究没有达到OS主要终点,治疗组和安慰剂组mOS分别为13个月和12.3个月。#临床研究失败#查看全文
美股滚雪球03-27 22:01
$Glycomimetics(GLYC)$ 在二季度发布 Topline data from pivotal Phase 3 study of Uproleselan in relapsed/refractory (R/R) AML,对股价影响很大。$传奇生物(LEGN)$ $美团-W(03690)$查看全文
牛唐2022-12-19 17:24
医药板块速评(2022.12.16)
1、$新泰医药(MDGL)$ 发布数据在即,后续走势如何看?
2、$Satsuma制药(STSA)、$Cabaletta Bio(CABA)、$Glycomimetics(GLYC)等毛票被热潮,哪些公司还有机会?
3、$Altimmune(ALT)$ 、$Ginkgo Bioworks(DNA)$ 、$Canopy Growth(CGC)等期权异动,后续走势如...查看全文
牛唐2022-11-21 17:34
医药板块速评(2022.11.18)
本期内容提示:
1、$Glycomimetics(GLYC)$ 半个月四倍,还有哪只医药股有类似潜力?
2、多家机构持仓披露,哪些医药股受到青睐?
3、$台积电(TSM)$ 、$苹果(AAPL)$ 、$Snap Inc.(SNAP)等期权异动,后续走势如何看?查看全文
牛唐2022-11-14 16:59
医药板块速评(2022.11.11)
本期内容提示:
1、多家医药股见底,哪些有配置机会?
2、$Glycomimetics(GLYC)$ 一周翻倍,是否有加仓机会?
3、$苹果(AAPL)、$Sea Limited(SE)期权异动,后续走势如何看?
$百度(BIDU)$ $再鼎医药(ZLAB)$查看全文
群氓鄙陋2022-02-11 22:58
回复@群氓鄙陋: $Glycomimetics(GLYC)$ 有戏吗?!//@群氓鄙陋:昨天的盘中脉冲就因为这个原因?最新的5%以上股东有什么值得重视的吗?查看全文
$GlycoMimetics(GLYC)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2016-06-27 AccNo: 0000921895-16-005013 Size: 241 KB 网页链接
$GlycoMimetics(GLYC)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2016-06-16 AccNo: 0001047469-16-013851 Size: 604 KB 网页链接
$GlycoMimetics(GLYC)$ 8-K - Current report Filed: 2016-06-10 AccNo: 0001558370-16-006351 Size: 1 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$GlycoMimetics(GLYC)$ 8-K - Current report Filed: 2016-06-02 AccNo: 0001558370-16-006259 Size: 78 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$GlycoMimetics(GLYC)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2016-06-02 AccNo: 0001558370-16-006257 Size: 141 KB 网页链接
$GlycoMimetics(GLYC)$ 8-K - Current report Filed: 2016-05-18 AccNo: 0001558370-16-006065 Size: 39 KBItem 5.07: Submission of Matters to a Vote of Security Holders 网页链接
$GlycoMimetics(GLYC)$ 8-K - Current report Filed: 2016-05-04 AccNo: 0001558370-16-005257 Size: 153 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$GlycoMimetics(GLYC)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2016-05-04 AccNo: 0001558370-16-005254 Size: 3 MB 网页链接
$GlycoMimetics(GLYC)$ DEF 14A - Other definitive proxy statements Filed: 2016-04-11 AccNo: 0001558370-16-004578 Size: 1 MB 网页链接
$GlycoMimetics(GLYC)$ 8-K - Current report Filed: 2016-03-29 AccNo: 0001558370-16-004451 Size: 610 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接